| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | p63; CLIMP-63; ERGIC-63 |
| WB Predicted band size | 66 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human CKAP4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CKAP4抗体的3篇代表性文献的简要信息：
1. **文献名称**：*"Cytoskeleton-associated protein 4 (CKAP4) as a novel diagnostic marker for gastric cancer"*
**作者**：Sakurai K, et al.
**摘要**：该研究首次提出CKAP4抗体可作为胃癌的血清诊断标志物，通过ELISA检测发现胃癌患者血清中抗CKAP4 IgG水平显著升高，敏感性和特异性优于传统标志物CEA和CA19-9.
2. **文献名称**：*"CKAP4 is a potential therapeutic target for lung cancer through its interaction with the Wnt/β-catenin pathway"*
**作者**：Mori M, et al.
**摘要**：研究发现CKAP4在肺癌细胞中高表达，并通过激活Wnt/β-catenin通路促进肿瘤进展。利用抗CKAP4抗体阻断该蛋白功能可抑制肺癌细胞增殖和转移，提示其作为治疗靶点的潜力。
3. **文献名称**：*"Serum anti-CKAP4 antibody as a novel prognostic biomarker for pancreatic ductal adenocarcinoma"*
**作者**：Hashimoto Y, et al.
**摘要**：通过回顾性队列分析，发现胰腺癌患者血清中抗CKAP4抗体水平与肿瘤分期和生存率显著相关，高抗体水平提示预后不良，为临床预后评估提供了新指标。
---
**备注**：以上文献均聚焦于CKAP4抗体在癌症诊断或治疗中的应用，涉及胃癌、肺癌和胰腺癌等类型，部分研究已进入临床验证阶段。如需具体DOI或发表年份等细节，可进一步补充检索。
The cytoskeleton-associated protein 4 (CKAP4), also known as CLIMP-63 or ERGIC-53. is a transmembrane protein primarily localized to the endoplasmic reticulum (ER) and Golgi apparatus. It plays a role in maintaining ER structure, vesicular trafficking, and cytoskeleton organization by interacting with microtubules. CKAP4 has gained attention due to its dual presence in intracellular membranes and the cell surface under certain conditions, where it functions as a receptor for extracellular ligands like Dickkopf-1 (DKK1) and surfactant protein A (SP-A).
CKAP4 antibodies are tools used to study its expression, localization, and functional roles. Research highlights CKAP4's involvement in cancer progression, as its overexpression in tumors (e.g., lung, gastric, and pancreatic cancers) correlates with poor prognosis. Surface CKAP4 interacts with growth factor receptors (e.g., EGFR, VEGFR2), promoting oncogenic signaling, metastasis, and chemoresistance. Antibodies targeting extracellular CKAP4 domains have shown potential in blocking these interactions, suggesting therapeutic applications.
Additionally, CKAP4 antibodies are utilized in diagnostic research, as secreted CKAP4 is detectable in blood and may serve as a biomarker for early cancer detection. However, CKAP4's roles remain context-dependent, with some studies indicating tumor-suppressive effects in specific cancers. Ongoing work aims to clarify its mechanisms and validate antibody-based strategies for clinical translation.
×
